Magenta Therapeutics (MGTA) Financials

$0.70

$-11.43 (-94.23%)

As on 11-Sep-2023 16:00EDT

Market cap

$45 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	58.57	80.90	74.69	78.70	82.97	59.96
Operating Profit (EBIT)	-42.48	-80.90	-74.69	-78.70	-82.97	-59.96
Other Income	5.70	4.44	3.56	3.77	6.20	--
Profit before Tax	-68.70	-76.46	-71.14	-74.94	-76.77	-57.52
Provision for Tax	-4.89	-4.44	-5.58	-5.74	-8.04	2.45
Profit after Tax (Net Income)	-69.81	-72.02	-65.56	-69.19	-68.73	-57.52
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-65.41	-76.46	-71.14	-74.94	-76.77	-57.60

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	74.60	105.96	172.67	143.91	141.19	145.65
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	26.14	6.40	6.28	6.21	1.25
Current Liabilities	4.03	14.55	10.86	11.43	14.12	10.42
Total Liabilities	82.67	146.65	189.93	161.62	161.51	157.31

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	--	31.04	13.01	10.09	11.67	11.99
Current Assets	78.64	115.60	176.93	151.53	149.84	145.32
Total Assets	82.67	146.65	189.93	161.62	161.51	157.31
Total Debt*	--	29.96	--	--	--	--
Net Current Assets	74.60	101.05	169.83	140.10	135.73	134.90

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-67.09	-59.53	-64.02	-57.10	-41.89
Cash Flow from Investing Activities	--	-9.81	43.43	-10.64	1.53	-91.70
Cash from Financing Activities	--	2.88	89.60	67.74	62.30	142.15
Net Cash Inflow / Outflow	--	-74.02	73.50	-6.92	6.73	8.56

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-1.17	-1.21	-1.12	-1.43	-1.76	-1.73
Cash EPS ($)	--	-1.18	-1.08	-1.39	-1.71	-1.71
Adjusted Book Value ($)	--	1.78	2.94	2.98	3.61	4.39
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.13	-1.01	-1.32	-1.46	-1.26
Free Cash Flow per Share ($)	--	-1.14	-1.03	-1.33	-1.54	-1.49

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-46.68	-41.42	-48.54	-47.92	-58.70
ROE (%)	-97.27	-51.70	-41.42	-48.54	-47.92	-58.70
ROA (%)	-51.89	-42.80	-37.30	-42.83	-43.11	-54.32
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	-1,223.90	-1,622.12	-1,843.64	-1,837.28	-1,108.48	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	47.30	-8.31	5.10	5.14	-38.37	-68.95
Net Profit Growth (%)	-11.67	-9.86	5.25	-0.68	-19.49	-62.06
EPS Growth (%)	12.89	-0.09	0.22	0.19	-0.02	-0.05
Book Value Growth (%)	-46.68	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.33	-3.97	-5.48	-8.62	-3.29
Price / Book Value	0.54	0.22	1.51	2.63	4.19	1.30
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.40	0.74	-1.15	-3.00	-5.50	-0.79
Close Price ($)	12.16	6.40	70.88	125.44	242.56	91.20
High Price ($)	35.84	87.84	227.20	254.40	336.00	261.28
Low Price ($)	5.12	5.12	70.40	92.16	86.56	84.96
Market Cap ($ Cr)	45.14	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	0.28	--	--	--	--
Short term debt to equity ratio	--	0.04	--	--	--	--
Current Ratio	19.49	7.95	16.29	13.26	10.62	13.95
Quick Ratio	19.49	--	--	--	--	--
Interest Coverage	-8.76	-18.22	-36.98	-20.90	--	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.